Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis"

Clin Cardiol. 2022 Jul;45(7):687-690. doi: 10.1002/clc.23852. Epub 2022 May 30.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Allopurinol / adverse effects
  • Febuxostat* / adverse effects
  • Gout Suppressants / adverse effects
  • Gout* / drug therapy
  • Humans

Substances

  • Gout Suppressants
  • Febuxostat
  • Allopurinol